Assenagon Asset Management S.A. Lowers Position in Zoetis Inc. $ZTS

Key Points

• Assenagon Asset Management cut its Zoetis stake by 52.3% in the second quarter, selling 426,077 shares and retaining 389,335 shares worth approximately $28 million. Institutional investors collectively own 92.8% of the company.
• Zoetis beat second-quarter earnings expectations with adjusted EPS of $1.87, but revenue of $2.47 billion fell short of estimates and was essentially flat year over year amid weaker veterinary traffic and competitive pressure.
• Zoetis lowered its fiscal 2026 outlook to adjusted EPS of $6.15–$6.25 and revenue of $9.1–$9.3 billion, contributing to the stock’s decline. Analysts maintain an average “Hold” rating with a $115.50 price target, while shares recently traded near $72.53.

Assenagon Asset Management S.A. decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 52.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 389,335 shares of the company's stock after selling 426,077 shares during the quarter. Assenagon Asset Management S.A. owned 0.09% of Zoetis worth $27,978,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of the stock. Byrne Asset Management LLC lifted its position in Zoetis by 55.8% during the second quarter. Byrne Asset Management LLC now owns 670 shares of the company's stock valued at $48,000 after purchasing an additional 240 shares during the last quarter. Sarasin & Partners LLP increased its stake in Zoetis by 5.6% in the second quarter. Sarasin & Partners LLP now owns 22,570 shares of the company's stock valued at $1,622,000 after acquiring an additional 1,200 shares during the last quarter. 180 Wealth Advisors LLC lifted its stake in Zoetis by 38.2% during the second quarter. 180 Wealth Advisors LLC now owns 3,484 shares of the company's stock worth $250,000 after purchasing an additional 963 shares during the last quarter. Integral Investment Advisors Inc. boosted its holdings in shares of Zoetis by 127.0% in the 2nd quarter. Integral Investment Advisors Inc. now owns 7,015 shares of the company's stock worth $504,000 after purchasing an additional 3,925 shares in the last quarter. Finally, Dynamic Advisor Solutions LLC boosted its holdings in shares of Zoetis by 3.9% in the 2nd quarter. Dynamic Advisor Solutions LLC now owns 9,156 shares of the company's stock worth $658,000 after purchasing an additional 344 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis reported second-quarter adjusted earnings of $1.87 per share, above the $1.84–$1.85 analyst consensus and up from $1.76 a year earlier. The earnings beat provides some support for the stock. Zoetis Surpasses Q2 Earnings Estimates
• Positive Sentiment: JPMorgan lowered its price target from $130 to $115 but maintained an Overweight rating, implying substantial potential upside from recent levels. The target reduction reflects more conservative estimates rather than a bearish long-term view.
• Neutral Sentiment: Zoetis appointed James “Jay” Saccaro as executive vice president and chief financial officer, with the announcement also describing an expanded finance and operating leadership role. The change may improve execution, but its near-term effect on results is unclear. Zoetis Appoints Jay Saccaro
• Negative Sentiment: Second-quarter revenue was $2.47 billion, below the $2.50 billion consensus and essentially flat year over year. Management cited weaker veterinary traffic, customer price sensitivity and competitive pressure in companion-animal products, with promotions being used to defend market share. ZTS Q2 Earnings Call Flags Deeper Companion Animal Pressure
• Negative Sentiment: Zoetis cut fiscal 2026 guidance to adjusted EPS of $6.15–$6.25 from expectations near $6.87, and revenue guidance to $9.1–$9.3 billion versus consensus of roughly $9.8 billion. The outlook reduction is the primary reason the stock has declined despite the quarterly earnings beat. Zoetis Q2 Earnings Beat Estimates, Revenues Miss, 2026 View Cut

Insiders Place Their Bets

In related news, Director Paul Bisaro acquired 2,000 shares of the business's stock in a transaction that occurred on Wednesday, May 13th. The stock was bought at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the purchase, the director owned 27,862 shares in the company, valued at $2,114,168.56. The trade was a 7.73% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Frank A. Damelio purchased 6,650 shares of the company's stock in a transaction on Wednesday, May 13th. The stock was purchased at an average price of $75.39 per share, with a total value of $501,343.50. Following the completion of the transaction, the director owned 21,458 shares of the company's stock, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.22% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

ZTS has been the subject of a number of research reports. Stifel Nicolaus cut their price objective on shares of Zoetis from $95.00 to $85.00 and set a "hold" rating for the company in a research note on Friday, June 26th. Wall Street Zen cut Zoetis from a "buy" rating to a "hold" rating in a report on Saturday, May 2nd. TD Cowen reduced their price target on Zoetis from $150.00 to $104.00 and set a "buy" rating on the stock in a research report on Tuesday, June 30th. JPMorgan Chase & Co. dropped their price objective on Zoetis from $130.00 to $115.00 and set an "overweight" rating for the company in a research note on Friday. Finally, William Blair reaffirmed a "market perform" rating on shares of Zoetis in a research note on Thursday. Seven research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and an average price target of $115.50.

Zoetis Trading Down 0.2%

NYSE ZTS opened at $72.53 on Monday. Zoetis Inc. has a 12 month low of $71.47 and a 12 month high of $160.48. The company has a current ratio of 3.08, a quick ratio of 1.84 and a debt-to-equity ratio of 2.87. The stock's fifty day moving average price is $76.66 and its 200-day moving average price is $100.58. The stock has a market cap of $30.41 billion, a P/E ratio of 11.95, a P/E/G ratio of 1.21 and a beta of 0.73.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The business had revenue of $2.47 billion for the quarter, compared to analysts' expectations of $2.50 billion. During the same period in the prior year, the firm posted $1.76 EPS. The firm's quarterly revenue was down .2% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities analysts forecast that Zoetis Inc. will post 6.43 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis's dividend payout ratio (DPR) is currently 34.93%.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source